About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches.
IP: Carme Santoyo Medina Collaborators: Jaume Sastre Garriga, Ingrid Galán Cartaña, Montserrat Janer Cabo, M Jesus Arevalo Navines, Medició del nivell d'activitat física i anàlisi dels factors associats a l'adherència en persones amb esclerosi múltiple, Helena Llorente Blasco Funding agency: Societat Catalano_Balear de Fisioteràpia Funding: 3000 Reference: SCBF/2023/SANTOYO Duration: 18/12/2023 - 17/12/2026
IP: Begoña Benito Villabriga Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido i Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Maria Jose Pérez García, Miguel Segura Ginard, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Cristina Auger Acosta, Neus Bellera Gotarda, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno Garcia del Blanco, Ana Vivancos Prellezo, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Sandra Mancilla Zamora, Ana Zabalza de Torres, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Gabriela Guillén Burrieza, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Jaume Capdevila Castillon, Nicolás Miguel Fissolo , Maria Nazarena Pizzi, Paolo Giovanni Nuciforo, Tian Tian, Andrea Guala , Juan Pablo Betancur Rengifo Funding agency: Instituto de Salud Carlos III Funding: 2494527.53 Reference: FORT23/00034 Duration: 01/01/2024 - 31/12/2027
IP: Susana Otero Romero Collaborators: Imane Boutitah Benyaich, Enrique Rodríguez Zafra, Blanca Borras Bermejo, Anna Falcó Roget, Mar Tintore Subirana, Ana Zabalza de Torres, Daniel Romero Herrero, Caracterización de las infecciones y de su impacto en pacientes con Esclerosis Múltiple en la era de los tratamientos inmunosu Funding agency: Instituto de Salud Carlos III Funding: 115000 Reference: PI23/01654 Duration: 01/01/2024 - 31/12/2026
IP: Carmen Tur Gomez Collaborators: Carlos Domínguez Pérez, Miriam Izquierdo Sans Funding agency: Instituto de Salud Carlos III Funding: 242500 Reference: CP23/00117 Duration: 01/01/2024 - 31/12/2028
An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.
A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.
The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.
Simoa HD1 equipment
2026 SIMOA HD1 Rates
PDF 0.47 MB
SIMOA HD1 Rates - historical
PDF 0.15 MB
